Name (Synonyms) | Correlation | |
---|---|---|
drug1371 | Lopinavir/Ritonavir 400 mg/100 mg Wiki | 0.71 |
drug770 | Digital cardiac Counseling Wiki | 0.71 |
drug3004 | sofosbuvir Wiki | 0.71 |
drug709 | Daclatasvir Wiki | 0.50 |
drug1220 | Interferon Beta-1B Wiki | 0.41 |
drug1372 | Lopinavir/ritonavir Wiki | 0.22 |
drug1822 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D002318 | Cardiovascular Diseases NIH | 0.15 |
D007239 | Infection NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.15 |
There are 2 clinical trials
A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir
Description: Time to negative NPS 2019-n-CoV RT-PCR
Measure: Time to negative NPS Time: Up to 1 monthDescription: Time to negative saliva 2019-n-CoV RT-PCR
Measure: Time to negative saliva Time: Up to 1 monthDescription: Time to NEWS of 0
Measure: Time to clinical improvement Time: Up to 1 monthDescription: Length of hospitalisation
Measure: Hospitalisation Time: Up to 1 monthDescription: 30-day mortality
Measure: Mortality Time: Up to 1 monthDescription: Cytokine/ chemokine changes
Measure: Immune reaction Time: up to 1 monthDescription: Adverse events during treatment
Measure: Adverse events Time: up to 1 monthDescription: Time to negative NPS, saliva, urine and stool 2019-n-CoV RT-PCR
Measure: Time to negative all clinical specimens Time: up to 1 monthSofosbuvir with and without ribavirin in treatment of COVID 19 Egyptian patients
Description: The total number of patients with response to treatment
Measure: Number of patients with response to treatment Time: 1 month